Clinical effect of nonthrombotic total parenteral nutrition catheters. 1984

P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg

Radiographic evidence of subclavian vein thrombosis has been shown to occur in 33% of total parenteral nutrition patients. This incidence can be significantly reduced to 8% when heparin is administered concomitantly in total parenteral nutrition solutions. To evaluate the thrombotic risk of a newly developed polyurethane catheter, 20 concurrent patient pairs were prospectively cannulated with either a standard polyethylene catheter plus heparin or a polyurethane catheter without heparin in a sequential statistical study. Radionuclide venograms (Tc99m) were performed within 72 hr of catheterization, at biweeky intervals, and at termination of total parenteral nutrition administration. No patient in either group developed clinical (pain, arm swelling, collateral veins) or venogram evidence of thrombosis after catheterization during an overall cannulation period of 820 days. Use of polyurethane catheters and elimination of heparin in total parenteral solutions may be particularly important since contraindications to heparin use are common. Additionally, heparin elimination can decrease admixture work and confusion (ie, subcutaneous heparin double dosing) without increasing the risk of subclavian vein thrombosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010288 Parenteral Nutrition The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously). Intravenous Feeding,Nutrition, Parenteral,Parenteral Feeding,Feeding, Intravenous,Feeding, Parenteral,Feedings, Intravenous,Feedings, Parenteral,Intravenous Feedings,Parenteral Feedings
D010289 Parenteral Nutrition, Total The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of TPN solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins. Hyperalimentation, Parenteral,Intravenous Hyperalimentation,Nutrition, Total Parenteral,Parenteral Hyperalimentation,Total Parenteral Nutrition,Hyperalimentation, Intravenous
D011095 Polyethylenes Synthetic thermoplastics that are tough, flexible, inert, and resistant to chemicals and electrical current. They are often used as biocompatible materials for prostheses and implants. Ethylene Polymers,Ethene Homopolymers,Homopolymers, Ethene,Polymers, Ethylene
D011140 Polyurethanes A group of thermoplastic or thermosetting polymers containing polyisocyanate. They are used as ELASTOMERS, as coatings, as fibers and as foams. Polyisocyanates,Ostamer,Pellethane,Spandex,Ostamers,Pellethanes,Polyisocyanate,Polyurethane,Spandices
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin

Related Publications

P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
January 1994, JPEN. Journal of parenteral and enteral nutrition,
P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
January 1995, JPEN. Journal of parenteral and enteral nutrition,
P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
April 1983, Lancet (London, England),
P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
January 1984, NITA,
P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
February 1983, Surgery, gynecology & obstetrics,
P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
November 1986, Surgery, gynecology & obstetrics,
P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
June 1996, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition,
P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
February 1990, Infection control and hospital epidemiology,
P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
July 1991, Infection control and hospital epidemiology,
P J Fabri, and J M Mirtallo, and M L Ebbert, and K A Kudsk, and C Powell, and R L Ruberg
July 2003, American journal of critical care : an official publication, American Association of Critical-Care Nurses,
Copied contents to your clipboard!